Florense Sibarani Ursula Regina, Magdalena Sinaga Bintang Yinke, Erna Mutiara
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Department of Pulmonology and Respiratory Medicine, Adam Malik Hospital, Medan, Indonesia.
Afr J Infect Dis. 2024 Oct 25;19(1):36-44. doi: 10.21010/Ajidv19i1.5. eCollection 2025.
Bacteria or fungi in COVID-19 involves several mechanisms that can affect immune system and also can increase severity of symptoms. The incidence of bacterial or fungal infections is common in patients with viral respiratory tract infections. The aim of this study was to determine the microbial patterns and sensitivity tests of bacterial and fungal infection in COVID-19 patients at National Referral Hospital in North Sumatra, Indonesia.
A cross-sectional design, where data was obtained from a 100 COVID-19 patients medical records, from December 2020 to April 2021. This study employed total sampling, those that fit the inclusion and exclusion criteria.
A total population of 100 COVID-19 patients were included, with bacterial infections in 26 patients (26%), fungi in 5 patients (5%), bacteria and fungi in 5 patients (5%). The most common bacterial pathogen was in 14 patients (45.1%), followed with in 5 patients (16.1%), in 5 patients (16.1%) and in 3 patients (9.6%). The most sensitive antibiotic in was Amikacin (57.14%). The most common fungal infection was in 5 patients (50.0%) and mostly sensitive to Fluconazole, Voriconazole, Caspofungin, Amphotericin B, Micafungin and Flucytosine (60.0%).
Bacterial and fungal infections can occur in COVID-19 patients, bacterial infection most commonly found in this study. The most sensitive antibiotic or anti-fungal is different for each bacterial or fungal found, and can be used as a basis for antibiotic selection for COVID-19 patients.
新型冠状病毒肺炎(COVID-19)中的细菌或真菌涉及多种可影响免疫系统且会加重症状严重程度的机制。病毒呼吸道感染患者中细菌或真菌感染的发生率很常见。本研究的目的是确定印度尼西亚北苏门答腊省国家转诊医院COVID-19患者细菌和真菌感染的微生物模式及药敏试验。
采用横断面设计,数据来自2020年12月至2021年4月100例COVID-19患者的病历。本研究采用全样本抽样,即符合纳入和排除标准的患者。
共纳入100例COVID-19患者,其中26例(26%)发生细菌感染,5例(5%)发生真菌感染,5例(5%)同时发生细菌和真菌感染。最常见的细菌病原体是[此处原文缺失具体细菌名称],14例(45.1%);其次是[此处原文缺失具体细菌名称],5例(16.1%);[此处原文缺失具体细菌名称],5例(16.1%);[此处原文缺失具体细菌名称],3例(9.6%)。[此处原文缺失具体细菌名称]中最敏感的抗生素是阿米卡星(57.14%)。最常见的真菌感染是[此处原文缺失具体真菌名称],5例(50.0%),且大多对氟康唑、伏立康唑、卡泊芬净、两性霉素B、米卡芬净和氟胞嘧啶敏感(60.0%)。
COVID-19患者可发生细菌和真菌感染,本研究中细菌感染最为常见。每种发现的细菌或真菌的最敏感抗生素或抗真菌药物不同,可为COVID-19患者的抗生素选择提供依据。